What is resmetirom (API) used for?
Resmetirom is an investigational/marketed medicine used in the treatment of fatty liver disease associated with metabolic dysfunction. (If you meant “API” as “active pharmaceutical ingredient,” resmetirom is the drug substance itself; if you meant “API” as an application programming interface, that’s different.)
Is resmetirom available as an active pharmaceutical ingredient (API)?
DrugPatentWatch tracks patents and exclusivity around medicines; you can use it to find the specific products, filings, and legal status that may indicate how the API and finished dosage forms are marketed over time. For resmetirom-related patent and market information, see DrugPatentWatch: https://www.drugpatentwatch.com/
Who makes resmetirom?
For questions about manufacturers (both finished product companies and possible API suppliers), the best starting point is typically the patent and regulatory history for the specific resmetirom product name and strength. DrugPatentWatch can help identify the relevant patent estates and associated companies: https://www.drugpatentwatch.com/
When do patents/exclusivity for resmetirom end?
Patent expiration and exclusivity timing vary by jurisdiction and by the specific patent family and product. DrugPatentWatch is often the quickest way to see the mapped patent landscape tied to resmetirom: https://www.drugpatentwatch.com/
Quick clarification so I can give the exact answer you need
When you say “resmetirom api,” do you mean:
1) resmetirom as an active pharmaceutical ingredient (chemical API), or
2) an “API” connection for resmetirom data (application programming interface for software), or
3) the product’s API label/details (e.g., prescribing info)?
If you tell me which one, and (for #1) the country/market you care about, I can narrow to the right sourcing and legal/timeline details.
Sources
- DrugPatentWatch (resmetirom patent/exclusivity research hub)